Adjuvant pegylated interferon alfa-2b improves RFS in stage III melanoma
The final results of EORTC 18991, a randomised phase III trial conducted by the EORTC Melanoma Group, have shown that in resected stage III melanoma, the use of adjuvant pegylated interferon alfa-2b improves the 4-year recurrence-free survival from 39% to 46%....
Want to read complete article? Please Sign in or Register.